Erkki Ruoslahti American medical researcher
Ruoslahti, Erkki.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Ruoslahti, E.
Ruoslahti, Erkki, 1940-
VIAF ID: 71279835 (Personal)
Permalink: http://viaf.org/viaf/71279835
Preferred Forms
-
100 0 _
‡a
Erkki Ruoslahti
‡c
American medical researcher
-
100 1 _
‡a
Ruoslahti, E.
-
100 1 0
‡a
Ruoslahti, Erkki
-
100 1 _ ‡a Ruoslahti, Erkki
-
100 1 _
‡a
Ruoslahti, Erkki
(sparse)
-
100 1 _ ‡a Ruoslahti, Erkki
-
100 1 _ ‡a Ruoslahti, Erkki
-
100 1 _ ‡a Ruoslahti, Erkki
-
100 1 _
‡a
Ruoslahti, Erkki
-
100 1 _
‡a
Ruoslahti, Erkki,
‡d
1940-
-
100 1 _ ‡a Ruoslahti, Erkki.
4xx's: Alternate Name Forms (5)
Works
| Title | Sources |
|---|---|
| Chemistry of tumor-associated antigens |
|
| Extracellular matrix components |
|
| Fibroblast surface protein |
|
| Immunoadsorbents in protein purification |
|
| In vivo cation exchange in quantum dots for tumor-specific imaging |
|
| Integrin Signaling and Matrix Assembly |
|
| iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. |
|
| Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. |
|
| Lymphangiogenesis and Cancer: Fig. 1 |
|
| Lymphatic zip codes in premalignant lesions and tumors. |
|
| Magnetic luminescent porous silicon microparticles for localized delivery of molecular drug payloads. |
|
| Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. |
|
| Metastasis of tumor cells is enhanced by downregulation of Bit1. |
|
| Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery |
|
| Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. |
|
| Mitochondrial p32 protein is a critical regulator of tumor metabolism via maintenance of oxidative phosphorylation. |
|
| Molecular changes in the vasculature of injured tissues |
|
| Molecular profiling of heart endothelial cells. |
|
| The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. |
|
| Nanoparticle amplification via photothermal unveiling of cryptic collagen binding sites |
|
| Nanoparticle-induced vascular blockade in human prostate cancer |
|
| Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain |
|
| Nanoparticles that communicate in vivo to amplify tumour targeting. |
|
| Neuropilin-1 and heparan sulfate proteoglycans cooperate in cellular uptake of nanoparticles functionalized by cationic cell-penetrating peptides. |
|
| New Insights into "Permeability" as in the Enhanced Permeability and Retention Effect of Cancer Nanotherapeutics. |
|
| New p32/gC1qR Ligands for Targeted Tumor Drug Delivery. |
|
| New way to activate caspases |
|
| Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels |
|
| Peptide-directed highly selective targeting of pulmonary arterial hypertension. |
|
| Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. |
|
| Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis. |
|
| Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion |
|
| Porous Silicon Nanoparticle Delivery of Tandem Peptide Anti-Infectives for the Treatment of Pseudomonas aeruginosa Lung Infections. |
|
| Precision Targeting of Tumor Macrophages with a CD206 Binding Peptide. |
|
| Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32. |
|
| Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. |
|
| Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies. |
|
| Protein kinase D is a positive regulator of Bit1 apoptotic function. |
|
| Proteolytic actuation of nanoparticle self-assembly. |
|
| Quantity and accessibility for specific targeting of receptors in tumours. |
|
| R-Ras is a global regulator of vascular regeneration that suppresses intimal hyperplasia and tumor angiogenesis. |
|
| Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. |
|
| Recombinant Decorin Fusion Protein Attenuates Murine Abdominal Aortic Aneurysm Formation and Rupture. |
|
| Reprogramming human retinal pigmented epithelial cells to neurons using recombinant proteins. |
|
| The RGD story: a personal account. |
|
| Selection of phage-displayed peptides on live adherent cells in microfluidic channels. |
|
| Selection strategies for anticancer antibody discovery: searching off the beaten path. |
|
| Selective Targeting of a Novel Vasodilator to the Uterine Vasculature to Treat Impaired Uteroplacental Perfusion in Pregnancy. |
|
| Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. |
|
| Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels |
|
| Specialization of tumour vasculature. |
|
| Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice |
|
| Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. |
|
| Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1 |
|
| Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. |
|
| Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes. |
|
| Synthetic surfaces for human embryonic stem cell culture. |
|
| Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting |
|
| Target-seeking antifibrotic compound enhances wound healing and suppresses scar formation in mice. |
|
| Targeted Antiscarring Therapy for Tissue Injuries. |
|
| Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma |
|
| Targeted quantum dot conjugates for siRNA delivery. |
|
| Targeted silver nanoparticles for ratiometric cell phenotyping. |
|
| Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4 |
|
| Targeting atherosclerosis by using modular, multifunctional micelles. |
|
| Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. |
|
| Targeting of albumin-embedded paclitaxel nanoparticles to tumors. |
|
| Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. |
|
| Targeting the prostate for destruction through a vascular address. |
|
| Tissue-penetrating delivery of compounds and nanoparticles into tumors. |
|
| TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells |
|
| Trophoblast cell activation by trophinin ligation is implicated in human embryo implantation |
|
| Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. |
|
| Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth. |
|
| Tumor-Targeted Multimodal Optical Imaging with Versatile Cadmium-Free Quantum Dots |
|
| Urokinase-controlled tumor penetrating peptide. |
|
| Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium. |
|
| Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment. |
|
| Vascular histomolecular analysis by sequential endoarterial biopsy in a shunt model of pulmonary hypertension |
|
